Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease ...

Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical ...

One question on everyone’s mind is what the impact of the midterm elections will be on the US healthcare system in the near ...

An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations ...

Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently ...

For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ...

Democratic senators are investigating 10 insurers’ role in the Trump administration’s termination of 760,000 ACA enrollees’ ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults ...

Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the ...

Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out ...

Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule ...